Compare VNET Group Inc (VNET) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VNET Group Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? VNET Group Inc trades at $7.5 (market cap $2.13B), while Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 62.3× VNET Group Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| VNET | VRTX | |
|---|---|---|
Market Cap | $2.13B | $132.79B |
Sector | Technology | Health |
52-Week High | $14.03 | $529.65 |
52-Week Low | $6.29 | $376.62 |
Enterprise Value | $5.28B | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VNET trades at $7.33, up 4.56% in the last 24 hours, but technical indicators signal a bearish trend with RSI near overbought levels. The company reported a net loss of $256.77 million in 2025, with negative profit margins and ROE, though revenue grew to $9.95 billion. Recent news highlights strategic investor entry and AI-driven demand boosting wholesale data center growth, with Q2 2026 earnings due August 18, 2026.
The outlook remains mixed: analyst consensus is 62.5% buy with a 54% upside target, but persistent losses and high debt-to-asset ratio pose risks. Investment opportunity hinges on execution of capacity expansions and AI demand, while volatility from options trading and legal settlements adds uncertainty.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
